Swiss Paediatric Oncology Group
The Swiss Paediatric Oncology Group (SPOG) is a non-profit organisation which for more than 40 years now has been committed to achieving better treatment options and a higher quality of life for children and adolescents suffering from cancer by means of patient-centred cancer research.
It is the aim of the SPOG to enable as many children and adolescents with cancer in Switzerland as possible to participate in a trial and receive the most effective therapy in accordance with the latest medical science, while maintaining the highest possible quality of life in the short and long term. This is achieved through quality-controlled treatment studies and continuous consultation within the SPOG, but also with international groups of experts.
Research activity explained simply
SPOG launched a touching animated film for Childhood Cancer Awareness Month
Trial on the treatment of malignant germ cell tumours
SPOG provides access to a new trial on a greater quality of life
For children with leukaemia and Down’s syndrome
The SPOG (Swiss Paediatric Oncology Group) gives you access to the new trial.
Better treatment options for children with renal tumours
Access to international therapy optimisation trial possible.
Honorary professorship for Prof. Katrin Scheinemann (MD)
University of Lucerne honours President of the SPOG.
Best possible therapies for malignant brain tumours
New trial for children and adolescents with high-risk medulloblastoma.
Clinical trial on the improved treatment of children and adolescents
SPOG trial for patients suffering from a high-risk neuroblastoma.
SPOG as a partner in the Race For Life 2021
Charity event for those affected by cancer and for promoting cancer research.
SPOG study wins Pfizer Research Prize
Christa König and Cécile Adam win Pfizer Research Prize 2021 with SPOG study.
Katrin Scheinemann becomes President of PanCare
The President of SPOG has been elected President of PanCare for the next three years.